# Rapid Micro Biosystems, Inc. (RPID) · Edgar & Edgarette company card

> Rapid Micro Biosystems (RPID) grew revenue 19.7% in FY2025 to $34 million, operating margin -141% against a -1.0% median for laboratory analytical instruments, equity 44.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1380106 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/RPID) · [JSON](https://www.pops4.com/boards/company/RPID.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $34M |
| Revenue growth, 1 year | 19.7% |
| Revenue growth per year | 9.7% |
| Operating margin | -141.1% (prior year -178.0%) |
| Net margin | -140.3% |
| Operating cash flow | −$31M |
| Capital spending | $850,000 |
| Free cash flow | −$32M |
| Cash | $20M |
| Long-term debt | $19M |
| Total assets | $75M |
| Total equity | $33M |
| Equity ÷ assets | 44.4% |
| Return on equity | -141.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -22.43 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late quarterly report notice in the last 12 months; operating cash flow was negative; operating loss: a margin of -141.1% in FY2025; revenue is hard to predict: its 80% range is ±50%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $33.6M (FY2025), total debt $18.9M. Experience: revenue up 19.7% on the year, up 9.7% a year over 4 years; operating margin -141.1%, up from -178.0%. Soundness: equity 44.4% of assets, return on equity -141.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $23.4M and $69.6M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $21.7M to $75.2M. A statistical range, not company guidance. Against peers (12 filers, $50M+ revenue, laboratory analytical instruments): operating margin -141.1% against a -1.0% median; growth 19.7% against 1.1%.

Range logged 2026-11-01, receipt 050551f79dffa11a, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-Q Late quarterly report notice: 1, latest 2026-11-16 ([filing](https://www.sec.gov/Archives/edgar/data/1380106/000138010626000115/0001380106-26-000115-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-03-27 ([filing](https://www.sec.gov/Archives/edgar/data/1380106/000138010626000045/0001380106-26-000045-index.htm))

## Recent filings

- 8-K · filed 2026-11-16 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1380106/000110465926128328/0001104659-26-128328-index.htm)
- 8-K · filed 2026-11-16 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1380106/000138010626000110/0001380106-26-000110-index.htm)
- 10-Q · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/1380106/000138010626000101/0001380106-26-000101-index.htm)
- 8-K · filed 2026-08-07 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1380106/000138010626000097/0001380106-26-000097-index.htm)
- 8-K · filed 2026-05-28 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1380106/000138010626000085/0001380106-26-000085-index.htm)
- 8-K · filed 2026-05-19 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1380106/000110465926063936/0001104659-26-063936-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001380106.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1380106

## Cite

POPS4, Edgar & Edgarette: Rapid Micro Biosystems, Inc. (RPID) company card, from the company's own SEC filings, accessed 2026-11-17, https://www.pops4.com/boards/company/RPID. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

